Management of Imatinib-Resistant CML Patients | Citedby Results | Onkologie | Karger Publishers

Skip to Main Content

Skip Nav Destination

Management of Imatinib-Resistant CML Patients

Onkologie (2007) 30 (11): 574–580.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells

Manlio Tolomeo
Stefania Grimaudo
Antonietta Di Cristina
Rosaria M. Pipitone
Luisa Dusonchet
Maria Meli
Lucia Crosta
Nicola Gebbia
Francesco Paolo Invidiata
Lucina Titone
Daniele Simoni

Cancer Letters (2008) 265 (2): 289.

Src inhibitors in breast cancer therapy

Stephen Hiscox
Robert I Nicholson

Expert Opinion on Therapeutic Targets (2008) 12 (6): 757.